- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00064987
Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism
Role of FSH in Human Gonadal Development
Study Overview
Status
Conditions
Detailed Description
Though steroid output of the testes is minimal during childhood, important changes take place that impact spermatogenic potential. Specifically, the number of Sertoli cells increases until testosterone secretion rises during puberty. In animal models, the proliferation of Sertoli cells appears to be regulated by follicle stimulating hormone (FSH) even though FSH levels in childhood are relatively low. At puberty, the number of Sertoli cells becomes fixed; however, the existing cell population then undergoes functional maturation. This switch from proliferation to maturation of Sertoli cells appears to result from rising levels of intratesticular testosterone.
FSH deficiency during testicular development results in decreased numbers of Sertoli cells, even if physiologic hormonal replacement therapy is introduced in adolescence or adulthood. The number of mature Sertoli cells appears to correlate with testicular size, sperm count, and future fertility. An improved understanding of the specific roles of FSH, luteinizing hormone (LH), and testosterone in testicular development may have direct clinical applications in the treatment of male infertility. This study will define the role of FSH in stimulating Sertoli cell proliferation in the human male.
Patients in this study will be randomized to receive either FSH and GnRH (Group 1) or GnRH alone (Group 2). Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will receive the same regimen of exogenous GnRH for 18 months without prior FSH administration.
All patients will undergo an initial assessment that includes an overnight 12-hour frequent blood sampling study, testicular ultrasound, and testicular biopsy. Patients will be followed through monthly study visits with blood tests and seminal fluid analysis. Patients will also have serial testicular ultrasounds to measure testicular growth. Patients in Group 1 will also have a second frequent blood sampling to measure LH, FSH, and testosterone and to confirm the absence of LH pulses.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- no history of spontaneous puberty
- clinical hypogonadism
- infantile testes (< 3 ml)
- no reproductive hormone therapy except testosterone
- Complete absence of normal LH pulses during 12-hour baseline frequent blood sampling and serum testosterone < 100 ng/dl
- Normal testing of the anterior pituitary gland
- Negative MRI of the hypothalamic-pituitary area
Exclusion Criteria
- Prior therapy with gonadotropins (FSH, hCG, or GnRH)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group 1 (FSH)
Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months.
Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months.
GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
|
Outpatient surgical procedure.
Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
75 IU subcutaneous injection daily for four months.
Other Names:
|
ACTIVE_COMPARATOR: Group 2 (GnRH)
Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months.
GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
Patients in Group 2 will not receive prior FSH administration.
|
Outpatient surgical procedure.
Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LH
Time Frame: month 4 of GnRH treatment
|
Average Luteinizing Hormone levels after treatment.
|
month 4 of GnRH treatment
|
FSH
Time Frame: month 4 of GnRH treatment
|
Average Follicle Stimulating Hormone levels after treatment.
|
month 4 of GnRH treatment
|
Testosterone
Time Frame: month 4 of GnRH treatment
|
Average Testosterone levels after treatment.
|
month 4 of GnRH treatment
|
Inhibin B
Time Frame: month 4 of GnRH treatment
|
Average Inhibin B Levels after treatment.
|
month 4 of GnRH treatment
|
Testicular Size (Volume)
Time Frame: at baseline and month 4 of GnRH treatment
|
Average testicular volume after treatment.
|
at baseline and month 4 of GnRH treatment
|
Sperm Count
Time Frame: month 4 of GnRH treatment
|
Average sperm count after treatment.
|
month 4 of GnRH treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fertility
Time Frame: 24 months
|
Participants actively seeking to conceive.
|
24 months
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002 Sep;87(9):4128-36. doi: 10.1210/jc.2002-020518.
- Pitteloud N, Hayes FJ, Boepple PA, DeCruz S, Seminara SB, MacLaughlin DT, Crowley WF Jr. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002 Jan;87(1):152-60. doi: 10.1210/jcem.87.1.8131.
- Hayes FJ, Pitteloud N, DeCruz S, Crowley WF Jr, Boepple PA. Importance of inhibin B in the regulation of FSH secretion in the human male. J Clin Endocrinol Metab. 2001 Nov;86(11):5541-6. doi: 10.1210/jcem.86.11.8031.
- Kumar PA, Pitteloud N, Andrews PA, Dwyer A, Hayes F, Crowley WF Jr, Dym M. Testis morphology in patients with idiopathic hypogonadotropic hypogonadism. Hum Reprod. 2006 Apr;21(4):1033-40. doi: 10.1093/humrep/dei444. Epub 2006 Jan 5.
- Dwyer AA, Sykiotis GP, Hayes FJ, Boepple PA, Lee H, Loughlin KR, Dym M, Sluss PM, Crowley WF Jr, Pitteloud N. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2013 Nov;98(11):E1790-5. doi: 10.1210/jc.2013-2518. Epub 2013 Sep 13.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Disorders of Sex Development
- Urogenital Abnormalities
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Disorder of Sex Development, 46,XY
- Kallmann Syndrome
- Hypogonadism
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Follicle Stimulating Hormone
- Hormones
Other Study ID Numbers
- U54HD028138-457
- U54HD028138 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kallmann Syndrome
-
Hospital for Children and Adolescents, FinlandEnrolling by invitationKallmann SyndromeFinland
-
Massachusetts General HospitalNational Institutes of Health (NIH)UnknownHypogonadotropic Hypogonadism | Amenorrhea | Kallmann's SyndromeUnited States
-
Centre Hospitalier Universitaire VaudoisUniversity of LausanneCompletedKallmann Syndrome | Idiopathic Hypogonadotropic Hypogonadism | Congenital Hypogonadotropic HypogonadismSwitzerland
-
Massachusetts General HospitalCompletedKallmann Syndrome | Hypogonadotropic Hypogonadism | GnRH DeficiencyUnited States
-
Massachusetts General HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...UnknownHypogonadotropic Hypogonadism | Amenorrhea | Kallmann's SyndromeUnited States
-
Massachusetts General HospitalCompletedKallmann Syndrome | Hypogonadotropic Hypogonadism | Puberty, Precocious | Puberty, Delayed | GnRH DeficiencyUnited States
-
Shanghai Jiao Tong University School of MedicineCompletedKallmann Syndrome | Hypogonadotropic HypogonadismChina
-
Beijing Children's HospitalUnknownKallmann Syndrome | Hypogonadotropic HypogonadismChina
-
Eunice Kennedy Shriver National Institute of Child...CompletedKallmann Syndrome | Hypogonadism | Gonadal DisorderUnited States
-
Tongji HospitalRecruitingInfertility | Kallmann Syndrome | Isolated Hypogonadotropic HypogonadismChina
Clinical Trials on Testicular biopsy
-
University of EdinburghUniversity of OxfordRecruitingChildhood Cancer | Fertility DisordersUnited Kingdom
-
Fundación IVIRecruitingDNA Damage | IVF | Oligospermia | ICSI | EmbryoSpain
-
University of PittsburghWashington University School of Medicine; University of Miami; University of... and other collaboratorsRecruitingCancer | Autoimmune DisordersUnited States
-
Odense University HospitalCompleted
-
Cliniques universitaires Saint-Luc- Université...RecruitingInfertility, Male | Klinefelter SyndromeBelgium
-
University of Colorado, DenverWithdrawn
-
Boston Children's HospitalCompleted
-
Centre Hospitalier Universitaire de NiceTerminatedTesticular CancerFrance
-
Hospices Civils de LyonCompletedKlinefelter SyndromeFrance
-
Hadassah Medical OrganizationUnknownOncology [See Also, Affected System]Israel